Search results
Results From The WOW.Com Content Network
Seagen Inc. (formerly Seattle Genetics, Inc.) is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody -based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington (a suburb of Seattle ), is the industry leader in antibody-drug conjugates or ADCs ...
Seattle Genetics, Inc. (NASDAQ:SGEN) shareholders will have a reason to smile today, with the analysts making...
Investors in Seattle Genetics, Inc. (NASDAQ:SGEN) had a good week, as its shares rose 8.3% to close at US$117...
Celebrations may be in order for Seattle Genetics, Inc. (NASDAQ:SGEN) shareholders, with the analysts delivering a...
Seattle Genetics, a cancer-focussed drug developer, will receive an upfront payment of $600 million under the agreement, while Merck will invest the $1 billion to buy 5 million shares of Seattle ...
ZymoGenetics, Inc was one of the oldest biotechnology / pharmaceutical companies in the USA, [1] based in Seattle, Washington. The company was involved in the development of therapeutic proteins. Located on Lake Union, the address of the ZymoGenetics headquarters was 1201 Eastlake Avenue East. [2]
It has been a very good year for Seattle Genetics and its investors. Sales of Adcetris posted solid results in its first full year on the market, and high-profile collaborations with AbbVie and ...
In September 2020, Merck acquired $1 billion of Seattle Genetics common stock, and agreed to co-develop ladiratuzumab vedotin. [123] [124] In November 2020, Merck announced it would acquire VelosBio for $2.75 billion, developer of VLS-101, an antibody-drug conjugate designed to target Tyrosine kinase-like orphan receptor 1 (ROR1) in both ...